CAR T-Cell Therapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy is an established treatment option for relapsed and refractory diffuse large B-cell, mantle cell, and follicular lymphomas, and for B-cell acute lymphoblastic leukemia. Now, investigators report outcomes of a phase 2 single-group, pharma-sponsored trial of the CAR T-cell product idecabtagene vicleucel (ide-cel), which targets the B-cell maturation antigen (BCMA). Eligible patients were adults with relapsed and refractory multiple myeloma who had received three or more prior regimens.

Following leukodepletion with fludarabine plus cyclophosphamide, 128 patients received a single CAR T-cell infusion at one of three target dose levels: 150×10⁶ (n=4), 300×10⁶ (n=70), or 450×10⁶ (n=54) cells. An addi…